Introduction: Eupomatia laurina are trees native to Australia and Papua New Guinea. The fruit of this species are consumed as a bushfood. Infusions and decoctions produced from leaves and bark have reputed antiseptic properties and were used traditionally to treat a variety of bacterial diseases. Despite this, E. laurina fruit solvent extractions have not been rigorously examined for antibacterial properties against many pathogens. Methods: The antimicrobial activity of E. laurina fruit solvent extractions was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous E. laurina fruit extracts inhibited the growth of a wide range of bacterial species. Growth of both gram positive and gram negative bacteria was inhibited by the E. laurina fruit extracts to approximately the same extent. With some noteable exceptions, the methanolic extracts were generally more potent than the aqueous extracts. The methanolic and aqueous E. laurina fruit extracts were particularly potent inhibitors of P. mirabilis growth, with MIC values as low as 83 µg/mL (aqueous extract against the P. mirabilis clinical isolate). The antibacterial activity of the methanolic E. laurina fruit extract was further investigated by growth time course assays which showed significant growth inhibition in cultures of K. pneumoniae and P. mirabilis within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for internal use as well as for topical uses. Conclusions: The lack of toxicity of the E. laurina fruit extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria partially validate the traditional usage of these species to treat bacterial diseases and indicate their potential in the development of antiseptic agents.
INTRODUCTION
Plants produce a wide variety of compounds, which in addition to giving them characteristic pigment, odour and flavour characteristics, may also have antimicrobial properties. 1 For thousands of years, traditional plant derived medicines have been used in most parts of the world and their use in fighting microbial disease is becoming the focus of intense study. 2, 3 Whilst much of the research into traditional medicinal plant use has focused on Asian, 4 African 5 and South American 6 plants, the therapeutic potential of the flora of Australia has been recognised for many thousands of years. The first Australians had well developed ethnopharmacological systems and understood the therapeutic properties of a wide variety of aromatic Australian plants. 7 Despite this, relatively few studies have rigo rously examined the antibacterial activity of Australian native plants, although recently there has been increased study in this field. Eupomatia laurina R. Br. (family Eupomatiaceae; commonly known as Bolwarra, native guava, copper laurel) is a smallmedium tree which is native to the Australian continent and Papua New Guinea which were used by Australian Aborigines as a traditional bushfood. Interestingly, we were unable to find confirmed reports of Aboriginal medicinal use of any part of E. laurina. In contrast, Papua New Guinea tribes have been reported to boil the leaves and stem bark and drink the infusion to treat diarrhoea and dysentery. 8 Previous studies have demonstrated the antibacterial activity of the leaves, stem bark 8 and root bark 9 of this species. In contrast, antibacterial studies of E. laurina fruit are lacking.
Several interesting phytochemical components have been identified in E. laurina bark extracts. In particular, several alkaloid components have been isolated from E. laurina root bark and identified as sampangine 
. 9 Interestingly, that study also reported broad spectrum antibacterial and antiprotozoal activity for the bark extract and all of the isolated compounds. Indeed, the extract and compounds inhibited the growth of all bacteria and protozoa screened. Broad spec trum antifungal activity was also reported, albeit at doses which would indicate only moderate to low growth inhibitory activity. Despite these promising earlier studies using other parts of this species, examination of the antibacterial properties and phytochemistry of the fruit from E. laurina is lacking. The current report was undertaken to screen E. laurina fruit for growth inhibitory properties against a panel of path ogenic bacteria. 
MATERIALS AND METHODS

Plant collection and extraction
Evaluation of antimicrobial activity
Antimicrobial activity of all plant extracts was determined using a modi fied disc diffusion assay. 1315 Briefly, 100 µL of each bacterial culture was grown in 10 mL of fresh nutrient broth until they reached a count of ~10 8 cells/mL. A volume of 100 µL of the bacterial suspension was spread onto nutrient agar plates and extracts were tested for antibacterial activity using 5 mm sterilised filter paper discs. Discs were infused with 10 µL of the plant extracts, allowed to dry and placed onto the inoculated plates. The plates were allowed to stand at 4°C for 2 h before incubation at 30°C for 24 h. The diameters of the inhibition zones were measured to the closest whole millimetre. Each assay was performed in at least triplicate. Mean values (± SEM) are reported in this study. Standard discs of ampicillin (10 µg) were obtained from Oxoid, Australia and were used as positive controls to compare antibacterial activity. Filter discs infused with 10 µL of distilled water were used as a negative control.
Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentration (MIC) of each extract against susceptible bacteria was determined as previously described. 16, 17 Briefly, the E. laurina extracts were diluted in deionised water and tested across a range of concentrations. Discs were infused with 10 µL of the test dilu tions, allowed to dry and placed onto inoculated plates. The assay was completed as outlined above and graphs of the zone of inhibition versus concentration were plotted for each extract. Linear regression was used to determine the MIC values of each extract.
Bacterial growth time course assay
Bacterial growth time course studies were performed as previously described. 18 Briefly, 3 mL of the susceptible ATCC reference bacterial cultures (Klebsiella pneumoniae (ATCC31488) and Proteus mirabilis (ATCC21721)) in nutrient broth were added to 27 mL nutrient broth containing 3 mL of 10 mg/mL methanolic plant extract to give a final concentration of 1000 µg/mL in the assay. The tubes were incubated at 
30
o C with gentle shaking. The optical density was measured hourly at 550 nm for a 6 h incubation period. Control tubes were incubated under the same conditions but without the extract. All assays were performed in triplicate.
Toxicity screening Reference toxin for toxicity screening
Potassium dichromate (K 2 Cr 2 O 7 ) (AR grade, ChemSupply, Australia) was prepared as a 4 mg/mL solution in distilled water and was serially diluted in artificial seawater for use in the Artemia franciscana nauplii bioassay.
Artemia franciscana nauplii toxicity screening
Toxicity was tested using an adapted Artemia franciscana nauplii lethality assay. 1921 Briefly, 400 µL of seawater containing approximately 48 (mean 47.8, n = 125, SD 10.3) A. franciscana nauplii were added to wells of a 48 well plate and immediately used for bioassay. A volume of 400 µL of diluted plant extracts or the reference toxin were transferred to the wells and incubated at 25 ± 1 o C under artificial light (1000 Lux). A 400 µL seawater negative control was run in triplicate for each plate. All treatments were performed in at least triplicate. The wells were checked at regular intervals and the number of dead counted. The nauplii were considered dead if no movement of the appendages was detected within 10 seconds. After 24 h, all nauplii were sacrificed and counted to determine the total % mortality per well. The LC 50 with 95% confidence limits for each treat ment was determined using probit analysis.
Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments. One way ANOVA was used to calculate statistical significance between control and treated groups with a P value < 0.01 considered to be statistically significant.
RESULTS
Liquid extraction yields and qualitative phytochemical screening
Extraction of 1 g of dried and powdered E. laurina fruit with solvents of varying polarity yielded dried extracts ranging from 102mg (hexane extract) to 269 mg (chloroform extract) ( Table 1 ). The aqueous (242 mg) and methanolic extracts (257 mg) also yielded relatively high levels of extracted materials. The dried extracts were resuspended in 10 mL of deionised water (containing 1% DMSO), resulting in the extract concentrations shown in Table 1 . Qualitative phytochemical studies showed that the higher polarity meth anol and water solvents extracted the greatest diversity and highest levels of phytochemicals. Both contained high levels of tannins as well as moderate levels of phenolics, saponins, flavonoids and anthraquinones. The ethyl acetate extract contained similar phytochemical classes, albeit generally at lower levels. Interestingly, despite extracting relatively large amounts of material, the chloroform and hexane extracts were devoid of all classes of phytochemicals screened. Due to their nonpolar nature, these extracts would be expected to contain high levels of lipids, hydro carbons etc. As our qualitative phytochemical studies did not screen for these compounds, they were not detected and other techniques are required to further examine the nature of these nonpolar components.
Antimicrobial activity
To determine the growth inhibitory activity of the E. laurina fruit extracts against the panel of pathogenic bacteria, aliquots (10 µL) of each extract were screened in the disc diffusion assay. The aqueous and meth anolic E. laurina fruit extracts inhibited a broad spectrum of the bacterial species screened (Figure 1) . The methanolic B. myrtifolia extract was a more potent growth inhibitor than the aqueous extract against most bacterial species (as assessed by the sizes of the zones of inhibition). Noteably, the opposite trend was noted for P. mirabilis growth inhibition, with the aqueous extracts inhibiting the reference and clinical strains by 11.3 ± 0.6 and 12.0 ± 1.0 mm respectively. This inhibition was parti cularly noteworthy compared to the inhibition by the ampicillin control (10 µg: inhibition zones of approximately 10 mm). In contrast, the meth anolic E. laurina fruit extract inhibited P. mirabilis growth by 9.3 ± 0.6 mm (reference strain) and 10.0 ± 0 mm (clinical isolate strain). The ethyl acetate and chloroform extracts also inhibited the growth of a range of bacteria (6 (43%) and 5 (36%) of the 14 bacterial species tested respec tively), albeit generally with substantially smaller inhibition zones than were recorded for methanolic and aqueous extracts. The hexane extract was generally devoid of growth inhibitory activity. Both gram positive and gram negative bacteria were approximately equally affected by the E. laurina fruit extracts. Of the 10 gram negative bacterial strains tested, 6 (60%) were inhibited by both the methanolic and aqueous E. laurina fruit extracts. In contrast, the methanolic and aqueous E. laurina fruit extracts each inhibited 3 of the 4 (75%) of the gram positive bacterial species tested. In contrast, gram negative bacteria were significantly more susceptible to the ethyl acetate and chloroform extracts than were the gram positive bacterial species. Indeed, 5 of the 10 gram negative bacteria (50%) and 1 of the 4 gram positive bacteria (25%) were susceptible to the ethyl acetate extract. This trend was even more evident for the chloroform extract, with the growth of 4 of the gram negative bacteria (40%) and none of the gram positive bacteria inhibited.
The antimicrobial efficacy was further quantified by determining the MIC values for each extract against the microbial species which were determined to be susceptible. The methanolic and aqueous E. laurina fruit extracts were potent growth inhibitors of several bacterial species (as judged by MIC; Table 2 ). P. mirabilis was the most susceptible bacteria to the E. laurina fruit extracts, with MIC values <200 µg/mL (<2 µg infused into the disc) recorded for the aqueous and methanolic extracts against both strains of the bacteria. The ethyl acetate extract was also a moderate P. mirabilis growth inhibitor, with MIC values of 1885 (reference P. mirabilis strain) and 1603 µg/mL (clinical isolate P. mirabilis strain). As P. mirabilis infection is a common cause of urinary tract infec tions and has also been identified as a trigger of rheumatoid arthritis, 22, 23 the aqueous and methanolic E. laurina fruit extracts have potential for the prevention of these diseases in genetically susceptible individuals.
Furthermore, the aqueous and methanolic extracts were also potent S. aureus and S. epidermidis growth inhibitors, with MIC values generally in the 500900 µg/mL range. The ethyl acetate extract was also a potent A. hydrophilia growth inhibitor (MIC <700 µg/mL). The aqueous and methanolic E. laurina fruit extracts were also moderate inhibitors of A. hydrophilia, albeit with MIC values >1000 µg/mL, indicating moderate growth inhibition. Moderate to low growth inhibition (or no inhibition) was noted for all other extract/bacterium combinations.
Bacterial growth time course assay
The antibacterial activity of the E. laurina extracts was further investi gated in the reference bacterial strains by bacterial growth time course assays in the presence and absence of the extract. Only the effect of the methanolic extract on the bacterial growth time course were evaluated as this extract was generally as potent or more potent than the other E. laurina extracts. Furthermore, the time course studies only examined the effect of the extracts on the reference strains which were inhibited in the screening studies (K. pneumoniae and P. mirabilis). The starting concentration of the extract used in these assays was 1000 µg/mL. The methanolic E. laurina extract significantly inhibited K. pneumoniae ( Figure 3a) and P. mirabilis (Figure 3b ) growth within 1 h, indicating a rapid antimicrobial action. Whilst K. pneumoniae growth was inhibited for at least the first 4 h of the time course, the bacteria were generally able to overcome this inhibition by 6 h, with the recorded turbidity not significantly different to that of the untreated control. This indicates that the growth inhibition of these bacteria was bacteriostatic for the methanolic E. laurina extract at the concentrations tested. In contrast, inhibition of P. mirabilis by the methanolic E. laurina extract was substantially more profound, with growth still significantly inhibited by the end of the 6 h time course study. This may indicate that these extracts have bactericidal activity against P. mirabilis at the dose tested. Indeed, the turbidity at 6 h was not greatly increased from the starting turbidity.
Quantification of toxicity
The toxicity of the E. laurina extracts was initially tested in the Artemia franciscana nauplii bioassay at a concentration of 2000 µg/mL ( Figure 4 ). All extracts induced low levels of mortality at 24 h, similar to the % mortality seen for the seawater control. By 48 h, the aqueous and methanolic extracts has begun to induce mortality significantly higher than that in the untreated control. As only the methanolic extract induced > 50% toxicity at 48 h, all other extracts were deemed to be nontoxic. In contrast, the potassium dichromate positive control induced mortality within 4 h (results not shown), with 100% mortality induction seen by 24 h. To further quantify the effect of toxin concentration on the induction of mortality, the extracts were serially diluted in artificial seawater to test across a range of concentrations in the Artemia nauplii bioassay (Table 3) . For comparison, serial dilutions of potassium dichromate were also tested. All extracts were determined to be nontoxic, with LC 50 values substan tially greater than 1000 µg/mL following 24 h exposure. Extracts with an LC 50 of greater than 1000 µg/mL towards Artemia nauplii have previously been defined as being nontoxic.
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DISCUSSION
Plant derived remedies are becoming increasingly sought after in the treatment of a myriad of diseases and disorders due both to their per ception of greater safety than synthetic drugs, and the failure of current drug regimens to effectively treat many diseases. Our study reports on the growth inhibitory properties of E. laurina fruit extracts against a panel of pathogenic bacteria, and on their toxicity. The gram positive and gram negative bacteria tested in this study demonstrated similar susceptibilities towards the E. laurina fruit extracts. In contrast, many previous studies with other plant species report a greater susceptibility of many bacterial species towards solvent extracts for South American, 24 African 25 and Australian plant extracts. 26, 27 Our study examined the ability of E. laurina fruit to inhibit the growth of a panel of medicinally important bacterial pathogens. The aqueous and methanolic extracts were identified as being particularly potent inhibitors of P. mirabilis. MIC values against the clinical P. mirabilis isolate strain of 125 and 83 µg/mL (aqueous extract) and 213 and 137 µg/mL (methanolic extract) were determined for the extracts against the reference and clinical strains respectively. As P. mirabilis can trigger rheumatoid arthritis in genetically susceptible individuals, 22,23 these extracts have potential for the development of rheumatoid arthritis inhibitory therapies. The methanolic extract also displayed moderate K. pneumoniae growth inhibitory properties, with MIC values 1774 and 2018 µg/mL for both the reference and clinical strains respectively. As K. pneumoniae can trigger ankylosing spondylitis in genetically susceptible individuals, 28,29 this extract may also be useful in the prevention of ankylosing spondylitis. The aqueous and methanolic E. laurina fruit extracts also were mod erate to good inhibitors of several other bacterial pathogens. Both the aqueous and methanolic E. laurina extracts were also good inhibitors of S. aureus and S. epidermidis growth (MICs 500900 µg/mL). As both of these bacteria are skin disease pathogens, the aqueous and methanolic E. laurina fruit extracts also may have applications as topical treatments of these diseases. Whilst a detailed investigation of the phytochemistry of the E. laurina fruit extracts was beyond the scope of our study, qualitative screening studies were used to determine the classes of compounds present. Several commanalities were noted: the most potent aqueous, methanolic and ethyl acetate extracts all contained relatively high levels of tannins and flavonoids. Many studies have reported potent growth inhibitory activities for a number of tannin compounds. Gallotannins have been Results represent the mean ± SEM of triplicate determinations.
reported to inhibit the growth of a broad spectrum of bacterial species 30 through a variety of mechanisms including binding cell surface molecules including lipotoichoic acid and prolinerich cell surface proteins, 31, 32 and by inhibiting glucosyltransferase enzymes. 33 Elligitannins are also highly potent inhibitors of bacterial growth, with MIC values as low as 62.5 µg/mL. 30, 32 Ellagitannins have also been reported to function via several antibiotic mechanisms including interaction with cytoplasmic oxidoreductases and by disrupting bacterial cell walls. 30, 32 Thus, it is likely that E. laurina fruit tannins may contribute to the inhibition of bacterial growth reported in our study.
It is likely that other phytochemical classes also contribute to the growth inhibitory properties of these extracts. Our qualitative phytochemical screening studies indicate that polyphenolics, flavonoids, saponins and cardiac glycosides were present in the E. laurina fruit extracts. Many studies have reported potent antibacterial activities for a wide variety of polyphenolic compounds, including many flavonoids. 39 Further phyto chemical evaluation studies and bioactivity driven isolation of active components is required to further evaluate the mechanism of bacterial growth inhibition. The findings reported here also demonstrate that all of the E. laurina fruit extracts were nontoxic towards Artemia franciscana nauplii, with LC 50 values substantially > 1000 µg/mL. Extracts with LC 50 values > 1000 µg/mL towards Artemia nauplii are defined as being nontoxic. 21 Whilst our preliminary toxicity studies indicate that these extracts may be safe for therapeutic use, studies using human cell lines are required to further evaluate the safety of these extracts. Furthermore, whilst these studies have demonstrated the potential of the E. laurina fruit extracts in the development of future antibiotic chemotherapeutics for the prevention and treatment of urinary tract infections, autoimmune diseases (parti cularly rheumatoid arthritis and ankylosing spondylitis) and some skin diseases, more work is required to isolate the inhibitory components and determine the mechanism of inhibition.
CONCLUSION
The results of this study demonstrate the potential of the E. laurina fruit as inhibitors of pathogenic bacteria growth. Furthermore, their lack of toxicity indicates than they are safe for internal as well as topical treatment. Further studies aimed at the purification and identification of bioactive components are needed to examine the mechanisms of action of these agents. The lethality of the E. laurina leaf extracts (2000 µg/mL), potassium dichromate (1000 µg/mL) and a seawater control. M = methanolic extract; W = aqueous extract; E = ethyl acetate extract; C = chloroform extract; H = hexane extract; NC = negative (seawater) control; PC = positive control (1000 µg/mL potassium dichromate). All bioassays were performed in at least triplicate and are expressed as mean ± SEM.
